RxSight (RXST) Cost of Revenue (2020 - 2026)

RxSight (RXST) has 7 years of Cost of Revenue data on file, last reported at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 22.69% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $29.3 million (down 29.77% YoY), and the FY2025 full-year result was $31.5 million, down 23.21% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.4 million, up from $7.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $11.4 million in Q4 2024 and bottomed at $5.2 million in Q1 2022.
• The 5-year median for Cost of Revenue is $8.5 million (2023), against an average of $8.4 million.
• The widest annual swing landed in 2022, when Cost of Revenue jumped 119.07%; it then tumbled 39.44% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $8.7 million in 2022, then advanced by 26.08% to $10.9 million in 2023, then gained by 4.58% to $11.4 million in 2024, then plunged by 35.72% to $7.3 million in 2025, then rose by 0.68% to $7.4 million in 2026.
• The last three Cost of Revenue figures came in at $7.4 million (Q1 2026), $7.3 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.

Peer Comparison